visiongain - Conferences

Diabetes and Diabetic Retinopathy

info@visiongain.com (visiongain) — Thu, 21 Jan 2010 00:00:00 GMT

21st - 22nd January 2010, BSG Conference Centre, London, UK
Set to double from $32bn to $64bn over the next 15 years, the global diabetes market is set for stellar growth as changing demographics and new therapies begin entering the clinic. Managing toxic glucose and fat concentrations in the vasculature remain significant challenges for diabetics. As the numbers of patients affected by the disease climbs, so secondary vascular and ophthalmic complications affecting patients continue to grow. With up to 50 million people currently affected by diabetic eye diseases and 100 million forecast by 2025, more effective therapeutics are desperately needed.

Glaucoma & Retinopathies 2010

info@visiongain.com (visiongain) — Mon, 21 Jun 2010 00:00:00 GMT

21st - 22nd June 2010, BsG Conference Centre, London, uK
With the number of older people and diabetics rising worldwide, the glaucoma and retinal disease markets will double by 2020. These will remain the largest and fastest-growing areas of the ophthalmic pharmaceuticals market, with combined worldwide revenues of $20bn by 2025.

7th Annual Pain Management

info@visiongain.com (visiongain) — Mon, 18 Oct 2010 00:00:00 GMT

18th - 19th October 2010, Balls Brothers Minster Pavement, London, UK
Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth in the global pain management marketplace. Recent issues involving patent expiries of top NSAID's drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years?

Biosimilars and Follow-On Biologics Americas

info@visiongain.com (visiongain) — Mon, 28 Feb 2011 00:00:00 GMT

28th February - 2nd March 2011, Hilton Boston/Financial District, Boston, USA
The Pharmaceutical Research and Manufacturers of America (PhRMA), estimates the cost of developing a new biologic (noted as some of the most expensive drugs) to be around $1.2 billion compared with $375 million to develop a biosimilar, making biosimilars an appealing business prospect for companies seeking cost savings. In March 2010, the US Congress passed the much awaited legislation which would give the US FDA the authority to approve generic versions of the innovator biologic drug.

2nd Annual Diabetes and Diabetic Retinopathy

info@visiongain.com (visiongain) — Wed, 15 Jun 2011 00:00:00 GMT

15th - 16th June 2011, Thistle City Barbican, London, UK
Diabetes is becoming an epidemic and is expected to reach $86.9 billion by 2025; world health organisation predicts that 4.4% of the world population will have diabetes by 2030. Of the 246 million people with diabetes about third have signs of diabetic retinopathy and about third of these might have vision-threatening retinopathy defined as severe retinopathy or macular oedema.

8th Annual Pain Management

info@visiongain.com (visiongain) — Mon, 04 Jul 2011 00:00:00 GMT

4th - 5th July 2011, The Thistle Westminster, London, UK
Pain management is a dynamic and fast-moving area of translational medicine. The global pain market is driven substantially by an ageing world population, with pain management already one of the highest priorities for healthcare authorities worldwide.

5th Lyophilisation

info@visiongain.com (visiongain) — Wed, 07 Sep 2011 00:00:00 GMT

7th - 9th September 2011, Thistle City Barbican, London, UK
Lyophilisation is one of the fastest growing markets, with estimated revenue of $1.77bn (for products and services) in 2009, total revenues in this market is expected to reach $3.25bn in 2015 and $6.15bn by 2025.

9th Biosimilars

info@visiongain.com (visiongain) — Wed, 05 Oct 2011 00:00:00 GMT

5th - 7th October 2011, Thistle City Barbican, London, UK
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars.

2nd Annual Cell-Based Assays 2011

info@visiongain.com (visiongain) — Tue, 11 Oct 2011 00:00:00 GMT

11th - 13th October 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS
It takes well over £500 million and between 10 and 12 years to develop a new drug. For every million compounds screened, approximately 250 make it to pre-clinical testing, 10 advance to clinical trials and just one is approved for patient use. Industry can ill-afford to continue such a wasteful process.

4th Pre-Filled Syringes

info@visiongain.com (visiongain) — Mon, 17 Oct 2011 00:00:00 GMT

17th - 19th October 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS
Join us at Visiongain's 4th Pre-filled syringes conference and gain insight into a spectrum of topical issues ranging from manufacture, formulation and drug identity to quality, safety and novel pre-filled syringe technologies.

3rd Annual Vaccine Manufacturing

info@visiongain.com (visiongain) — Thu, 27 Oct 2011 00:00:00 GMT

27th - 28th October 2011, Thistle City Barbican, London, UK
The global vaccine market will achieve sustained growth over the next 15 years, and this trend is likely to continue as governments recognise the importance of mass vaccination. Visiongain's 3rd Annual Vaccine Manufacturing conference will feature key industry experts, who will assess the current landscape of vaccine development and address challenges faced by manufacturers.

5th Annual Stability Testing

info@visiongain.com (visiongain) — Thu, 03 Nov 2011 00:00:00 GMT

3rd - 4th November 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Pharmaceutical companies are under intense pressure to provide safe, effective medicines for patient consumption while also maintaining adherence to stringent regulatory and quality requirements. Stability testing is a highly integral part of pharmaceutical product development which constitutes one of the fastest growing markets in the pharmaceutical and biotechnology sectors.

4th Annual Biomarkers

info@visiongain.com (visiongain) — Thu, 01 Dec 2011 00:00:00 GMT

1st - 2nd December 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Forecasters predict significant growth in the global market of biomarkers with estimates of $26.5 billion by the year 2015. This growth will be driven by the current demand for biomarkers in drug discovery and other areas of R&D. The use of biomarkers during early stages of a product development is already saving costs and time in the industry by indicating the possibility of failure at an earlier stage in the research process. CROs have now recognised the commercial opportunities of biomarkers and are forming partnerships with providers and building in-house capabilities.

5th Annual Contract Manufacturing

info@visiongain.com (visiongain) — Wed, 07 Dec 2011 00:00:00 GMT

7th - 8th December 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
The importance and role of contract manufacturing has changed over the years from solely providing efficiencies in cost, capacity and time-to-market, or a specific expertise not available in-house to unique, innovative, and state-of-the-art processes and production technology to the pharmaceutical industry.

5th Annual Recombinant Antibodies

info@visiongain.com (visiongain) — Tue, 17 Jan 2012 00:00:00 GMT

17th - 19th January 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
From Kohler and Millstein's pioneering efforts to today's multifactorial approach, monoclonal antibodies have consistently improved the clinical outcome of disease progression. As shown by Avastin and Lucentis, antibodies have blockbuster potential, now number eight of today's 20 top-selling biotech drugs. With ongoing growth rates nearing 15%, the global market will reach $74.7 by 2024 as new approvals and a growing world population drive patient demand.

5th Pharmaceutical Product Lifecycle Management

info@visiongain.com (visiongain) — Tue, 24 Jan 2012 00:00:00 GMT

24th - 25th January 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Research shows that pharmaceutical companies spend approximately 19% of their total revenue on activities that fall under the heading of pharmaceutical lifecycle management (PLM). With many blockbuster drugs drawing closer to the end of their patents, R&D new chemical entity output declining and the current economic climate; the utilisation of product lifecycle management is set to increase as pharmaceutical companies look for ways to optimise revenue.

7th Annual Pharmacovigilance Conference

info@visiongain.com (visiongain) — Mon, 30 Jan 2012 00:00:00 GMT

30th - 31st January 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
The importance of Pharmacovigilance has been apparent since the problems with thalidomide emerged in the 1960s. Since then, various high profile drug recalls, and estimations that more than 750,000 injuries and deaths each year in the US are caused by adverse drug reactions, have meant tightened regulatory controls.

Biobanking 2012

info@visiongain.com (visiongain) — Thu, 09 Feb 2012 00:00:00 GMT

9th - 10th February 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
As researchers strive to develop more personalised medicines, the acquisition of high quality biospecimens is vital. This is reflected in the estimation that the biobanking market will be worth $19.13 bn by 2015. Harmonising biobank operations with better communication networks and global standardisation is imperative. The biobanking and biomolecular resources research infrastructure's new model for research estimates they will have approximately 200 biobanks operating across Europe by early 2012, complying with clearly defined responsibilities, quality standards and common procedures.

2nd Lyophilization Americas

info@visiongain.com (visiongain) — Tue, 06 Mar 2012 00:00:00 GMT

6th - 8th March 2012, The Seaport Hotel, Boston, USA
With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today. Mirroring this trend the market for lyophilizing compounds such as biologicals and biopharmaceuticals is currently approaching 200 million units and it is set to continue its year-on-year double digit growth. The lyophilisation market is expected to achieve significant growth from 2011 to 2021, owing primarily to greater demand for injectable biotech drugs and vaccine market expansion caused by the entry of new products and technologies.

10th Biosimilars Americas

info@visiongain.com (visiongain) — Tue, 13 Mar 2012 00:00:00 GMT

13th - 15th March 2012, The Seaport Hotel, Boston, USA
Biologics constitutes a major share of expenditure in the USA and globally. It is one of the fastest growing sectors of the pharmaceutical industry which corresponds to over 15% of the total pharmaceutical market. There is a large and potentially lucrative demand for lower cost biological drugs worldwide. With favourable regulatory developments, the biosimilar sector should pick up significantly, however, forming an important developing pharma market.

9th Annual Pain Management Conference

info@visiongain.com (visiongain) — Wed, 18 Apr 2012 00:00:00 GMT

18th - 19th April 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Pain is a global phenomenon which affects the quality of life that many people experience. It is not specific to any group, yet causes major disruptions in the workforce leading to economic and productivity losses. Pain management involves complex treatment sometimes with several medications and the input of a multidisciplinary team of health professionals. It also provides an ever expanding market for big pharma companies to provide new and more effective treatments.

6th Annual Diabetes Conference

info@visiongain.com (visiongain) — Wed, 25 Apr 2012 00:00:00 GMT

25th - 26th April 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Diabetes still remains an incurable disease which is affecting an increasing number of people in the world. This provides an expanding and resilient market for pharmaceutical management of the disease. The US market alone is expected to grow from $56.7Bn to $73.6Bn from 2015 to 2021. Diabetes is now a global disease due to an increasingly aging and sedentary population, with strong growth expected in emerging markets that will drive near term growth in diagnostics and uptake of pharmaceuticals.

3rd Annual Pre-Filled Syringes Americas

info@visiongain.com (visiongain) — Mon, 14 May 2012 00:00:00 GMT

14th - 16th May 2012, The Seaport Hotel, Boston, USA
The intravenous route of administration is the most effective route to administer medication fast and directly into the blood stream to facilitate the absorption and immediate onset of action, it also avoids 1st pass metabolism to increase the amount of active drug present. Other methods of administration may provide more comfort to the patient but have yet to be able reproduce the same rapid onset of action. Therefore parenteral administration is unlikely to be replaced in the near future.

8th Monoclonal Antibodies

info@visiongain.com (visiongain) — Wed, 23 May 2012 00:00:00 GMT

23rd - 24th May 2012, Thistle City Barbican, London, UK
Generating annual sales of almost $50bn per year monoclonal antibodies continue to play a vital role in the biopharmaceutical development and represent 42% of the total market. Anticipated steady growth at an annual rate of 6.9% suggests the revenues will reach over $63bn/year by 2015. Primarily driven by the oncology and autoimmune disease treatments, the industry's window will be significantly widened by the introduction of mAbs with novel indications and increasing penetration of the emerging economies.

2nd Annual Biobanking Americas 2012

info@visiongain.com (visiongain) — Wed, 13 Jun 2012 00:00:00 GMT

13th - 14th June 2012, The Seaport Hotel, Boston, USA
Biobanking offers immense opportunities for the entire pharmaceutical market, potentially opening ways to new drug discovery, and personalized medicine. It is not surprising the sector is expanding at such a rate that its total sales are predicted to triple in the next decade and reach $37.62bn by 2022, growing at CAGR of 15.7%. Visiongain's Biobanking Americas 2012 Conference will highlight the latest technological advances in the biobanking sector, most recent progress in the implementation of standard operating procedures, and current social perspective on the biobanking industry.

7th Annual Pharmaceutical Anti-Counterfeiting

info@visiongain.com (visiongain) — Tue, 26 Jun 2012 00:00:00 GMT

26th - 27th June 2012, Thistle City Barbican, London, EC1V 8DS, UK
Counterfeit medications are becoming a huge problem for many aspects of the pharmaceutical community from big pharma companies, through to wholesalers and down to end user level where patients are affected. The FDA estimates that 10% of the global market is counterfeit however there is no accurate way to measure this.

Cell Based Assays Americas

info@visiongain.com (visiongain) — Thu, 19 Jul 2012 00:00:00 GMT

19th - 20th July 2012, The Seaport Hotel, Boston, USA
Drugs recalls due to toxicity not only have a huge effect on the cost of developing new therapeutics but it also leads to many years of wasted research. That is why it is vital to get things right from the outset with more precise testing of new leads using more accurate in-vitro models. High Throughput Screening using biochemical assays has been a mainstay of the pharmaceutical industry in the past, but with the cost of developing a single lead reaching exorbitant amounts, it is now necessary to look at more cost-efficient methods that more accurately represent the in-vivo environment.

6th Lyophilisation

info@visiongain.com (visiongain) — Tue, 04 Sep 2012 00:00:00 GMT

4th - 6th September 2012, Thistle City Barbican, London, EC1V 8DS, UK
Lyophilisation continues to maintain a dominant position among the preservation techniques for various biopharmaceuticals. Currently over 50% of medicinal products must be freeze-dried due to their instability in the liquid state. Recent estimates of the market value of the sector suggest it is worth over $1.99bn, and constant introduction of new biologic drugs will drive further demand for lyophilisation services and technologies.

11th Annual Biosimilars UK

info@visiongain.com (visiongain) — Mon, 29 Oct 2012 00:00:00 GMT

29th - 31st October 2012, Holiday Inn Kings Cross/Bloomsbury, London, WC1X 9HX, UK
With a patent cliff looming in the future, the market for biological therapeutics is looking to undergo radical changes. Both producers of branded drugs and upstarts looking to meet the demand for cost-effective healthcare, will be looking to find the best strategies and solutions to compete in this dynamic environment. It is more critical than ever to make sure your company's plan to tackle the issues of litigation, pricing and reimbursement, regulatory approval and risk management meet the benchmarks set by industry leaders.

Single-Use Bioreactors

info@visiongain.com (visiongain) — Thu, 01 Nov 2012 00:00:00 GMT

1st - 2nd November 2012, Thistle Barbican, Clerkenwell, EC1V 8DS, UK
In the bioreactors market, disposables are one of the fastest growing sectors with the potential for many new breakthroughs and applications in the coming years. They are an attractive alternative to the traditional large inflexible stainless steel bioreactors which require substantial capital expenditure. The industry as a whole is experiencing an increased demand for biologics which requires the use of bioreactors to cultivate specific cell lines. The number of clinical monoclonal antibodies (mAbs) in development is increasing and pharmaceutical companies are looking at developing a diverse pipeline of mAbs to fill several smaller niches and meet the demand for personalised medicine rather than large scale production of blockbusters. This has resulted in the industry demanding smaller batch sizes, quicker turnover rates and cheaper production costs as budgets are restrained.

5th Pre-Filled Syringes

info@visiongain.com (visiongain) — Tue, 20 Nov 2012 00:00:00 GMT

20th - 21st November 2012, Holiday Inn Kings Cross/Bloomsbury, 1 Kingscross Road, WC1X 9HX, UK
Pre-filled syringes constitutes one of the fastest growing markets in the drug delivery and packaging sectors with total revenues in this market expected to reach $5.5bn in 2025. It continues to offer one of the highest growth potentials in the pharmaceutical industry with 20% CAGR over the past 5 years.

3rd Cell-Based Assays UK

info@visiongain.com (visiongain) — Wed, 06 Feb 2013 00:00:00 GMT

6th - 7th February 2013, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Cell-Based Assays (CBA) investigate the in vivo properties and effects of a drug molecule due to the cells ability to replicate normal processes that would occur in the body. With the cost of developing a new drug for market launch estimated to be over $1bn, this method of drug testing has the potential to save pharmaceutical companies millions through "fail early" techniques. These allow companies to detect any adverse effects that may occur in human cells that may not have been detected in animal cells. This can limit the chances of a medication failing in late stage clinical testing.

12th Biosimilars Americas

info@visiongain.com (visiongain) — Mon, 15 Apr 2013 00:00:00 GMT

15th - 17th April 2013, The Seaport Hotel, Boston, USA
The global pharmaceutical biological drug market is one of the fastest growing sectors generating revenue of $114.8bn in 2010, which corresponds to over 15% of the total pharmaceutical market. There is a large and potentially lucrative demand for lower cost biological drugs worldwide. Following the huge success of our events in Boston and London, the 12th Annual Biosimilars conference will face important questions associated with cost-effective methods of developing biosimilars, key regulatory issues, safety assessments both clinical & non-clinical methods and the future of biosimilars.

4th Biobanking UK

info@visiongain.com (visiongain) — Thu, 20 Jun 2013 00:00:00 GMT

20th - 21st June 2013, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
The Biobanking conference 2013 - will bring together industry experts from around the world to discuss the crucial issues and current trends in Biobanking. This two day event will focus on various aspects including ethical considerations, automated sample handling, open innovation initiatives and the latest developments and maintenance procedures.

7th Lyophilization Americas

info@visiongain.com (visiongain) — Tue, 15 Oct 2013 00:00:00 GMT

15th - 16th October 2013, The Seaport Hotel, Boston, USA
Visiongain's 7th Lyophilization Americas conference will examine the most pertinent issues on developing an optimized scale- up of the lyophilization cycle from the laboratory to a production scale. Vital questions will be answered on cost effectiveness for lyophilization, key analytical tools and technologies utilized in the process of lyophilization and regulations for lyophilized biotherapeutics with a key insight into the future.